- Home
- JHS vs ATRA Comparison
JHS vs ATRA Comparison
Compare JHS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHS | ATRA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5M | 38.9M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JHS | ATRA |
|---|---|---|
| Price | $11.01 | $5.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.6K | ★ 298.0K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.62 | $3.92 |
| 52 Week High | $12.09 | $19.15 |
Technical Indicators
Market Signals| Indicator | JHS | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 44.76 |
| Support Level | $11.01 | $4.27 |
| Resistance Level | $11.40 | $5.80 |
| Average True Range (ATR) | 0.10 | 0.69 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 4.62 | 17.69 |
Price Performance
Historical ComparisonAbout JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).